- Home
- LPG vs AGIO Comparison
LPG vs AGIO Comparison
Compare LPG & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LPG | AGIO |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2014 | 2013 |
Fundamental Metrics
Financial Performance| Metric | LPG | AGIO |
|---|---|---|
| Price | $39.04 | $33.71 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $39.33 | $38.88 |
| AVG Volume (30 Days) | 695.3K | ★ 898.0K |
| Earning Date | 05-21-2026 | 04-29-2026 |
| Dividend Yield | ★ 8.26% | N/A |
| EPS Growth | ★ 112.15 | N/A |
| EPS | ★ 4.54 | N/A |
| Revenue | ★ $481,511,242.00 | $43,011,000.00 |
| Revenue This Year | $35.73 | $76.75 |
| Revenue Next Year | N/A | $170.73 |
| P/E Ratio | $8.81 | ★ N/A |
| Revenue Growth | ★ 36.27 | N/A |
| 52 Week Low | $23.76 | $22.24 |
| 52 Week High | $48.12 | $46.00 |
Technical Indicators
Market Signals| Indicator | LPG | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 40.75 | 69.45 |
| Support Level | $24.30 | $26.71 |
| Resistance Level | $48.12 | $36.07 |
| Average True Range (ATR) | 1.64 | 1.51 |
| MACD | -0.53 | 0.62 |
| Stochastic Oscillator | 10.13 | 92.86 |
Price Performance
Historical ComparisonAbout LPG Dorian LPG Ltd.
Dorian LPG Ltd is an international liquefied petroleum gas shipping company focused on owning and operating gas carriers, or VLGCs. The company currently owns and operates around 22 modern VLGCs, including nineteen new fuel-efficient 84,000 cbm ECO-design VLGCs. Dorian LPG has offices in Connecticut, USA, London, United Kingdom, and Athens, Greece. IT operates in one reportable segment, the international transportation of LPG.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.